Quantification of AAV particle titers by infrared fluorescence scanning of coomassie-stained sodium dodecyl sulfate-polyacrylamide gels

Human Gene Therapy Methods

Volumn 23, Issue 3, 2012, Pages 198-203

  Kohlbrenner, Erik ^a   Henckaerts, Els ^b   Rapti, Kleopatra ^a   Gordon, Ronald E ^a   Michael Linden, R ^b   Hajjar, Roger J ^a   Weber, Thomas ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAZOLENE SODIUM; BRILLIANT BLUE; PROTEIN; COOMASSIE BRILLIANT BLUE; FUCHSINE;

ADENO ASSOCIATED VIRUS; AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ARTICLE; CLINICAL PROTOCOL; COMPARATIVE STUDY; DILUTION; FLUOROSCOPY; GENETIC PURITY; GENOME; LIMIT OF DETECTION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEPARATION TECHNIQUE; SEROTYPE; SILVER STAINING; THERMOGRAPHY; VIRUS CAPSID; VIRUS LOAD; VIRUS PARTICLE; WILD TYPE; ELECTRON MICROSCOPY; FLUORESCENCE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; INFRARED RADIATION; METHODOLOGY; SEQUENCE ANALYSIS; STANDARD; ULTRASTRUCTURE; VIRION;

CAPSID; DEPENDOVIRUS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENCE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; INFRARED RAYS; MICROSCOPY, ELECTRON; ROSANILINE DYES; SEQUENCE ANALYSIS, PROTEIN; VIRION;

EID: 84872014212     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.049     Document Type: Article

References (23)

1. Abramoff, M., Magalhaes, P., and Ram, S. (2004). Image processing with ImageJ. Biophot. Int. 11, 36-42.
2. Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: Poised at the clinical crossroads. Mol. Ther. 20, 699-708.
3. Aurnhammer, C., Haase, M., Muether, N., et al. (2012). Universal real-time PCR for the detection and quantification of adenoassociated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods 23, 18-28.
4. Ayuso, E., Mingozzi, F., Montane, J., et al. (2010). High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency. Gene Ther. 17, 503-510.
5. Becerra, S.P., Koczot, F., Fabisch, P., and Rose, J.A. (1988). Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J. Virol. 62, 2745-2754.
6. Fagone, P., Wright, J.F., Nathwani, A.C., et al. (2012). Systemic errors in quantitative polymerase chain reaction titration of selfcomplementary adeno-associated viral vectors and improved alternative methods. Hum. Gene Ther. Methods 23, 1-7.
7. Grimm, D., Kern, A., Rittner, K., and Kleinschmidt, J.A. (1998). Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9, 2745-2760. (Pubitemid 29027018)
8. Grimm, D., Kern, A., Pawlita, M., et al. (1999). Titration of AAV-2 particles via a novel capsid ELISA: Packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6, 1322-1330. (Pubitemid 29359028)
9. Jessup, M., Greenberg, B., Mancini, D., et al. (2011). Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2 +-ATPase in patients with advanced heart failure. Circulation 124, 304-313.
10. Johnson, F.B., Ozer, H.L., and Hoggan, M.D. (1971). Structural proteins of adenovirus-associated virus type 3. J. Virol. 8, 860-863.
11. Kuck, D., Kern, A., and Kleinschmidt, J.A. (2007). Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J. Virol. Methods 140, 17-24. (Pubitemid 46185591)
12. Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
13. Lock, M., McGorray, S., Auricchio, A., et al. (2010). Characterization of a recombinant adenoassociated virus type 2 Reference Standard Material. Hum. Gene Ther. 21, 1273-1285.
14. Luo, S., Wehr, N.B., and Levine, R.L. (2006). Quantitation of protein on gels and blots by infrared fluorescence of Coomassie blue and fast green. Anal. Biochem. 350, 233-238. (Pubitemid 43332823)
15. Maguire, A.M., High, K.A., Auricchio, A., et al. (2009). Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet 374, 1597-1605.
16. Maheshri, N., Koerber, J.T., Kaspar, B.K., and Schaffer, D.V. (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198-204. (Pubitemid 43221704)
17. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365, 2357-2365.
18. Rapti, K., Louis-Jeune, V., Kohlbrenner, E., et al. (2012). Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol. Ther. 20, 73-83.
19. Rohr, U.P., Wulf, M.A., Stahn, S., et al. (2002). Fast and reliable titration of recombinant adenoassociated virus type-2 using quantitative real-time PCR. J. Virol. Methods 106, 81-88. (Pubitemid 35279652)
20. Sommer, J.M., Smith, P.H., Parthasarathy, S., et al. (2003). Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol. Ther. 7, 122-128. (Pubitemid 36305364)
21. Wright, J.F. (2008). Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther. 15, 840-848. (Pubitemid 351712617)
22. Zeltner, N., Kohlbrenner, E., Clement, N., et al. (2010). Nearperfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther. 17, 872-879.
23. Zolotukhin, S., Byrne, B.J., Mason, E., et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973-985. (Pubitemid 29295202)